Strengths of this study are the high number of eyes included with completely documented follow-up before and after COVID-19, the strict inclusion criteria in terms of real delay, the concept of natural history visual loss in longer than usual appointment intervals, and diversity of regimes and anti-VEGF drugs used. The gene discussed is VEGFA; the disease is COVID-19.